Cargando…

Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment

OBJECTIVES: This study aims to assess the different delays of rheumatoid arthritis (RA) patients’ journey from disease onset to treatment initiation and to identify possible influencing factors. PATIENTS AND METHODS: This cross-sectional study included a total of 100 patients (14 males, 86 females;...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazaa, Alia, Bettaieb, Hiba, Sellami, Meriem, Miladi, Saoussen, Ouenniche, Kmar, Souebni, Leila, Kassab, Selma, Chekili, Selma, Zakraoui, Leith, Abdelghani, Kaouther, Laatar, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish League Against Rheumatism 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326372/
https://www.ncbi.nlm.nih.gov/pubmed/35949866
http://dx.doi.org/10.46497/ArchRheumatol.2022.8469
_version_ 1784757269998600192
author Fazaa, Alia
Bettaieb, Hiba
Sellami, Meriem
Miladi, Saoussen
Ouenniche, Kmar
Souebni, Leila
Kassab, Selma
Chekili, Selma
Zakraoui, Leith
Abdelghani, Kaouther
Laatar, Ahmed
author_facet Fazaa, Alia
Bettaieb, Hiba
Sellami, Meriem
Miladi, Saoussen
Ouenniche, Kmar
Souebni, Leila
Kassab, Selma
Chekili, Selma
Zakraoui, Leith
Abdelghani, Kaouther
Laatar, Ahmed
author_sort Fazaa, Alia
collection PubMed
description OBJECTIVES: This study aims to assess the different delays of rheumatoid arthritis (RA) patients’ journey from disease onset to treatment initiation and to identify possible influencing factors. PATIENTS AND METHODS: This cross-sectional study included a total of 100 patients (14 males, 86 females; mean age: 56.5±12.4 years; range, 26 to 82 years) who met the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for RA between January 2019 and January 2020. Demographic and clinical data and disease characteristics were collected from the patient interviews and medical files. Five different intervals were defined from symptom onset until the initiation of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). RESULTS: The mean age at RA onset was 46.6±12.4 years. Median delays from onset of symptoms until general practitioner (GP) and rheumatologist consultations were six (range, 0.25 to 240) months and 12 (range, 0 to 242) months, respectively. Median delays from onset of symptoms to RA diagnosis and treatment with csDMARDs were 15.7 (range, 2 to 252) months and 18 (range, 2 to 270) months, respectively. The mean number of consultations was 7.3±4.2 and the median number of physicians visited before the diagnosis was three (range, 1 to 8). The RA diagnosis delay was associated with rural geographic environment (p=0.02), lack of social insurance (p=0.027), progressive symptoms onset (p=0.006), morning stiffness (p=0.023), being initially examined by a GP (p=0.02), number of consultations (p<0.001; r=0.49), and number of physicians consulted before diagnosis (p=0.001; r=0.33) respectively. Based on the patients’ self-perception, the main causes of this long delay were lack of financial means (33%), wait times until exploration results (31%), wait times until the first GP or rheumatologist visit (26%), and geographical difficulty in accessing healthcare services (18%). CONCLUSION: Our study results suggest that patients with RA experience a significant delay until diagnosis and initiation of treatment. Healthcare providers should urgently consider factors related to diagnosis delay to shorten RA patients’ journey.
format Online
Article
Text
id pubmed-9326372
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Turkish League Against Rheumatism
record_format MEDLINE/PubMed
spelling pubmed-93263722022-08-09 Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment Fazaa, Alia Bettaieb, Hiba Sellami, Meriem Miladi, Saoussen Ouenniche, Kmar Souebni, Leila Kassab, Selma Chekili, Selma Zakraoui, Leith Abdelghani, Kaouther Laatar, Ahmed Arch Rheumatol Original Article OBJECTIVES: This study aims to assess the different delays of rheumatoid arthritis (RA) patients’ journey from disease onset to treatment initiation and to identify possible influencing factors. PATIENTS AND METHODS: This cross-sectional study included a total of 100 patients (14 males, 86 females; mean age: 56.5±12.4 years; range, 26 to 82 years) who met the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for RA between January 2019 and January 2020. Demographic and clinical data and disease characteristics were collected from the patient interviews and medical files. Five different intervals were defined from symptom onset until the initiation of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). RESULTS: The mean age at RA onset was 46.6±12.4 years. Median delays from onset of symptoms until general practitioner (GP) and rheumatologist consultations were six (range, 0.25 to 240) months and 12 (range, 0 to 242) months, respectively. Median delays from onset of symptoms to RA diagnosis and treatment with csDMARDs were 15.7 (range, 2 to 252) months and 18 (range, 2 to 270) months, respectively. The mean number of consultations was 7.3±4.2 and the median number of physicians visited before the diagnosis was three (range, 1 to 8). The RA diagnosis delay was associated with rural geographic environment (p=0.02), lack of social insurance (p=0.027), progressive symptoms onset (p=0.006), morning stiffness (p=0.023), being initially examined by a GP (p=0.02), number of consultations (p<0.001; r=0.49), and number of physicians consulted before diagnosis (p=0.001; r=0.33) respectively. Based on the patients’ self-perception, the main causes of this long delay were lack of financial means (33%), wait times until exploration results (31%), wait times until the first GP or rheumatologist visit (26%), and geographical difficulty in accessing healthcare services (18%). CONCLUSION: Our study results suggest that patients with RA experience a significant delay until diagnosis and initiation of treatment. Healthcare providers should urgently consider factors related to diagnosis delay to shorten RA patients’ journey. Turkish League Against Rheumatism 2021-10-13 /pmc/articles/PMC9326372/ /pubmed/35949866 http://dx.doi.org/10.46497/ArchRheumatol.2022.8469 Text en Copyright © 2022, Turkish League Against Rheumatism https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Article
Fazaa, Alia
Bettaieb, Hiba
Sellami, Meriem
Miladi, Saoussen
Ouenniche, Kmar
Souebni, Leila
Kassab, Selma
Chekili, Selma
Zakraoui, Leith
Abdelghani, Kaouther
Laatar, Ahmed
Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment
title Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment
title_full Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment
title_fullStr Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment
title_full_unstemmed Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment
title_short Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment
title_sort journey of rheumatoid arthritis patients in tunisia: from symptoms to treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326372/
https://www.ncbi.nlm.nih.gov/pubmed/35949866
http://dx.doi.org/10.46497/ArchRheumatol.2022.8469
work_keys_str_mv AT fazaaalia journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT bettaiebhiba journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT sellamimeriem journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT miladisaoussen journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT ouennichekmar journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT souebnileila journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT kassabselma journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT chekiliselma journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT zakraouileith journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT abdelghanikaouther journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment
AT laatarahmed journeyofrheumatoidarthritispatientsintunisiafromsymptomstotreatment